Results 101 to 110 of about 44,321 (338)
Antibody Engineering for Pursuing a Healthier Future [PDF]
, 2017 Since the development of antibody-production techniques, a number of immunoglobulins have been developed on a large scale using conventional methods. Hybridoma technology opened a new horizon in the production of antibodies against target antigens of ...
Abdullah F. U. H. Saeed +3 more
core +1 more source
Antibody‐Empowered Nanomedicine for Precise Biomedical Applications
Advanced Science, EarlyView.This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen +7 more
wiley +1 more source
Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer [PDF]
, 2017 Background: One bottleneck for adoptive T cell therapy (ACT) is recruitment of T cells into tumors. We hypothesized that combining tumor-specific T cells, modified with a marker antigen and a bispecific antibody (BiAb) that selectively recognizes ...
Abken, Hinrich +17 more
core
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter [PDF]
, 2016 Ad vectors are promising delivery vehicles for cancer therapeutic interventions. However, their application is limited by promiscuous tissue tropism and hepatotoxicity. This limitation can be avoided by altering the native tropism of Ads so that they can
Bhatia, Shilpa +4 more
core +3 more sources
Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases
Advanced Science, EarlyView.This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo +5 more
wiley +1 more source
BMC BiotechnologyBackground The World Health Organization (WHO) recommends combination therapy with two non-overlapping monoclonal antibodies (mAbs) to enhance protection in Rabies post-exposure prophylaxis (PEP).
Zhigao Zhang +4 more
doaj +1 more source
Supplementary Fig. S5 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design [PDF]
, 2023 Nam-Kyung Lee +3 more
openalex +1 more source
Extramedullary Disease—Achilles Heel in Myeloma?
American Journal of Hematology, EarlyView.ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar +7 more
wiley +1 more source
A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo
American Journal of Hematology, EarlyView.ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong +5 more
wiley +1 more source
Bispecific antibody for lung cancer: mechanisms and clinical insights
Frontiers in ImmunologyLung cancer is a refractory malignancy. Although various therapeutic options, including targeted therapies, immune checkpoint inhibitors, and systemic chemotherapy, have significantly improved the prognosis of lung cancer patients, five-year survival ...
Wei Chen, Afang Zhou, Yunfeng Zhou
doaj +1 more source